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Abstract
Background: The COVID-19 pandemic continues to rage on, and clinical research has been promoted worldwide.
We aimed to assess the clinical and methodological characteristics of treatment clinical trials that have been set
forth as an early response to the COVID-19 pandemic.
Methods: First, we reviewed all registered clinical trials on COVID-19. The World Health Organization International
Trials Registry Platform and national trial registries were searched for COVID-19 trials through April 19th, 2020. For
each record, independent researchers extracted interventions, participants, and methodological characteristics.
Second, on September 14th, 2020 we evaluated the recruitment status and availability of the results of COVID-19
treatment trials previously identified.
Results: In April 2020, a total of 580 trials evaluating COVID-19 treatment were registered. Reporting quality was
poor (core participant information was missing in 24.1 to 92.7%). Between 54.0 and 93.8% of the trials did not plan
to include older people or those with a higher baseline risk. Most studies were randomised (67.9%), single-centre
(58.3%), non-industry-funded (81.1%), to be conducted in China (47.6%), with a median duration of 184 days and a
median sample size of 100 participants. Core endpoints (mortality, clinical status, and hospitalization length) were
planned to be assessed in 5.2 to 13.1% of the trials. Five months later, 66 trials (11.4%) were reported as
“Completed”, and only 46 (7.9%) had public results available. One hundred forty-four of 580 trials (24.8%) either had
the status “Not yet recruiting” or “Suspended”, and 18 (3.1%) trials were prematurely stopped (“Terminated” or
“Withdrawn”) The number of completed trials and trials with results are much lower than anticipated, considering
the planned follow-up.
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Conclusions: Our results raise concerns about the success of the initial global research effort on COVID-19
treatment. The clinical and methodological characteristics of early COVID-19 treatment trials limit their capability to
produce clear answers to critical questions in the shortest possible time.
Keywords: COVID-19, Clinical trials, Meta-research, Trial methodology, Clinical endpoints
Background
Since December 2019, SARS-CoV-2 has caused a global
outbreak of a respiratory illness termed coronavirus
disease (COVID-19). COVID-19 ranges from mild, self-
limiting respiratory tract illness to severe progressive
pneumonia, multiorgan failure, and death [1, 2]. To date,
there are no therapeutic agents specifically designed for
the treatment of COVID-19. Fierce medical research is
currently underway, however, there are historical reasons
that led us to question if the global research community
is maximizing the expected benefit from these efforts
[3]. To shed some light on this question we decided to
assess the clinical and methodological characteristics of
treatment clinical trials set forth as an early response to
the COVID-19 pandemic.
Previous analyses of COVID-19-related studies have
been published focusing on scientific articles on
COVID-19, and registered studies beyond clinical trials
[4]. We aim to focus on clinical trial records, providing a
deeper insight into the methodological characteristics
that help to assess the capability of clinical research in a
pandemic context. COVID-related clinical trials have
already been recognized to lack features that optimize
their scientific value [5]. We intend to add a further
perspective providing a follow-up of the early-phase re-
search and review the output of early COVID-19 treat-
ment trials.
Methods
Registry search and trial selection
The World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) contains the
trial registration datasets provided by 17 clinical trial
registries [6]. It is anticipated that the great majority of
ongoing clinical trials are captured and recorded by the
databases [7]. We searched the ICTRP for completed
and ongoing COVID-19 trial records through April
19th, 2020 using the search terms “COVID-19”, “SARS-
Cov-2”, “2019-nCoV”, “severe acute respiratory syn-
drome coronavirus 2”, “2019 novel coronavirus” and
“COVID”. We also searched the three main national
clinical trial registries, namely ClinicalTrials.gov, the EU
Clinical Trials Register (EUCTR), and the Chinese Clin-
ical Trial Registry (ChiCTR).
We included all interventional trials, irrespective of
the intervention under investigation. We excluded
duplicate trial entries and trials that did not directly ad-
dress COVID-19. We did not exclude trials due to in-
complete data reporting.
Data extraction
Independent authors selected the trials registered up to
April 19th, 2020, extracted data into a pre-piloted
spreadsheet (supplementary material), and classified
each trial as seeking to assess a treatment or prophylac-
tic effect, or both. For each record, we extracted the type
of intervention, methodological aspects of the study
design, and participant characteristics. We assessed
whether or not trials plan to include participants with
known risk factors for poorer outcomes in COVID-19
[1, 2], namely cancer, chronic obstructive pulmonary
disease (COPD), diabetes, heart disease, hypertension, or
immunodeficiency.
For each trial identified, we extracted the updated re-
cruitment status on September 14th, 2020, alongside the
reasons for trials being prematurely stopped when avail-
able. We also assessed the registries for any submitted
results or indexed publications on the same date. Add-
itionally, we checked for publications of results of the
previously identified trials in WHO’s Global Research on
Covid-19 Database [8], Cochrane Covid-19 Study Regis-
ter [9], and selected living systematic reviews on covid-
19 [10, 11].
Analysis
We conducted statistical analyses using the R software
(version 3.6.1). We calculated descriptive statistics to
characterize data. We performed statistical comparisons
between post hoc defined groups using the Chi-Squared
and Kruskal-Wallis tests. We deemed P values of 0.05
statistically significant, with tests being two-sided.
Sample size estimates
We conducted sample size calculations using different
baseline scenarios for case fatality rates (CFR) for the
control group (2, 5, and 10%), as the true CFR is largely
unknown [12] and liable to change over time. Neverthe-
less, we recognize that a 2% CFR may be lower than that
observed in settings recruiting mostly high-risk patients.
We considered different possible treatment effects. All
sample size calculations considered a significance level
of 0.05 and a power of 80%.
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Results
We found 693 records of clinical trial protocols (supple-
mentary material), 648 (93.5%) on COVID-19, and 45
(6.5%) on COVID-related conditions (notably pulmonary
rehabilitation or exercise and mental health among
health care workers).
Among COVID-19 trials, 572 (88.3%) evaluated treat-
ment only (Table 1), 68 (10.5%) evaluated prophylaxis
only, and eight (1.2%) evaluated both. Our results focus
on the 580 trials evaluating COVID-19 treatment.
Quality of reporting
The quality of reporting across the trial registries is glo-
bally poor. In trial protocols covering COVID-19 treat-
ment, the maximal inclusion age was not specified in
332 protocols (57.2%), while 159 (27.4%) and 197
(34.0%) failed to report whether participants with severe
or critical disease forms were to be included, respect-
ively. Additionally, we could not assess whether patients
with known risk factors for poorer outcomes would be
included in 74.8% (regarding the inclusion or exclusion
of patients with an immunocompromised state) and
93.8% (regarding the inclusion or exclusion of partici-
pants with hypertension) of the protocols.
COVID-19 treatment trials interventions
Most trials (349 of 580, 60.2%) studied pharmacotherapy
(drug medicines), though 92 (15.9%) studied traditional
Chinese medicine (TCM). The remaining trials (25.0%)
evaluated mesenchymal stem cells and natural killer
cells, advanced life support strategies, convalescent
plasma and immunoglobulins, and other interventions
(Table 1).
Those protocols for which clinical data were available,
less than half had planned to include participants over
the age of 80 (19.7%), patients at a critical stage (21.4%),
and patients with known risk factors for poorer out-
comes (range, 1.6 to 5.5%). When comparing pharmaco-
therapy, TCM, and trials evaluating other treatment
interventions, we found notable differences in the pro-
portion of trials that planned to include patients with a
severe (P < 0.001) or critical status (P < 0.001) at baseline,
both were smaller among trials evaluating TCM (Fig. 1).
In those protocols for which methodological data were
available, most trials were non-industry-funded (81.1%),
used a randomised design (67.9%), and were conducted
in China (47.6%), irrespective of the intervention under
evaluation. Less than half the trials (41.7%) planned to
have more than one centre and only 3.0% planned to in-
clude centres from countries on different continents
(Fig. 2). Core clinical outcomes (mortality, clinical status
evaluated with WHO scales, and length of
hospitalization) were assessed as primary endpoints in
only a minority of trials (range, 5.2 to 13.1%). The most
commonly reported primary endpoints were respiratory
measures (97, 20.8%). The planned median sample size
and trial duration were 100 participants (interquartile
range, 50 to 260) and 184 days (interquartile range, 94 to
365), respectively. When comparing pharmacotherapy,
TCM, and trials evaluating other treatment interven-
tions, we found notable differences in the proportion of
trials that were randomised controlled trials (RCTs) and
in planned median sample sizes (Fig. 3). Pharmacother-
apy trials had the highest proportion of RCTs (P <
0.001), while trials evaluating other treatment interven-
tions had the lowest planned median sample sizes (P <
0.001).
Pharmacotherapy trials for COVID-19 treatment
The clinical and methodological characteristics of these
trials are detailed in the supplementary material.
Of the 349 trials that sought to evaluate drug treat-
ments for COVID-19, most (111, 31.8%) evaluated
chloroquine/hydroxychloroquine. Additionally, 89
(25.5%) evaluated antivirals, 65 (18.6%) assessed mono-
clonal antibodies, and 42 (12.0%) assessed a form of
interferon, immunomodulators, or immunosuppressants.
Notably, the proportion of trials that included patients
with a severe or critical illness at baseline were different
between these groups (P < 0.001 for both): the inclusion
of these populations was greater among trials evaluating
monoclonal antibodies (89.5 and 45.8%, respectively)
and smaller among trials evaluating antivirals (43.9 and
13.2%, respectively). The proportion of trials including
patients with COPD, diabetes, cancer, or immunodefi-
ciency was also different across these treatment groups,
with the inclusion of these populations greater in chloro-
quine/hydroxychloroquine trials and smaller in antiviral
trials (table and figure in the supplementary material).
The planned median trial sample sizes and study dura-
tions were also larger in chloroquine/hydroxychloro-
quine trials and smaller in antiviral trials (table and
figure in the supplementary material).
Sample size estimates
We performed sample size calculations for different
baseline scenarios for CFR of 2, 5, and 10% in the con-
trol group while considering different possible treatment
effects on mortality. Regarding registered trials with
mortality as a primary endpoint, and assuming a baseline
risk of 2%, only three trials were sufficiently powered to
detect a difference of 50% or more between treatment
groups (supplementary material).
Availability of results and recruitment status in
September 2020
On September 14th, 2020 we assessed the recruitment
status and availability of results of the 580 treatment
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Number of trials – no.
(%)
349 (60) 92 (16) 39 (7) 27 (5) 35 (6) 44 (8)
Maximal inclusion age – no. (%)
≥ 65 115 (33) 56 (61) 26 (67) 10 (37) 12 (34) 17 (39)
≥ 80 61 (17) 26 (28) 7 (18) 9 (33) 6 (17) 6 (14)
Not specified or
unknowna
228 (65) 32 (35) 12 (31) 17 (63) 20 (57) 27 (61)
Inclusion of severe COVID-19 – no. (%)
Yes 174 (50) 23 (25) 28 (72) 16 (59) 22 (63) 16 (36)
No 86 (25) 30 (33) 2 (5) 10 (37) 4 (11) 14 (32)
No information 89 (26) 39 (42) 9 (23) 1 (4) 9 (26) 14 (32)
Inclusion of critical COVID-19 – no. (%)
Yes 70 (20) 3 (3) 12 (31) 17 (63) 16 (46) 8 (18)
No 165 (47) 48 (52) 9 (23) 6 (22) 9 (26) 22 (50)
No information 114 (33) 41 (45) 18 (46) 4 (15) 10 (29) 14 (32)
Inclusion of participants with cancer – no. (%)
Yes 15 (4) 3 (3) 0 (0) 0 (0) 0 (0) 1 (2)
No 49 (14) 31 (34) 27 (69) 3 (11) 4 (11) 11 (25)
No information 285 (82) 58 (63) 12 (31) 24 (89) 31 (89) 32 (73)
Inclusion of participants with COPD – no. (%)
Yes 16 (5) 3 (3) 0 (0) 1 (4) 0 (0) 0 (0)
No 31 (9) 31 (34) 7 (18) 3 (11) 3 (9) 6 (14)
No information 302 (87) 58 (63) 32 (82) 23 (85) 32 (91) 38 (86)
Inclusion of participants with diabetes – no. (%)
Yes 16 (5) 0 (0) 0 (0) 1 (4) 0 (0) 0 (0)
No 16 (5) 11 (12) 2 (5) 3 (11) 1 (3) 6 (14)
No information 317 (91) 81 (88) 37 (95) 23 (85) 34 (97) 38 (86)
Inclusion of participants with heart disease – no. (%)
Yes 30 (9) 0 (0) 0 (0) 1 (4) 0 (0) 1 (2)
No 52 (15) 23 (25) 3 (8) 1 (4) 4 (11) 5 (11)
No information 267 (77) 69 (75) 36 (92) 25 (93) 31 (89) 38 (86)
Inclusion of participants with hypertension – no. (%)
Yes 19 (5) 2 (2) 0 (0) 1 (4) 0 (0) 0 (0)
No 8 (2) 4 (4) 0 (0) 1 (4) 0 (0) 1 (2)
No information 322 (92) 86 (93) 39 (100) 25 (93) 35 (100) 43 (98)
Inclusion of immunocompromised participants – no. (%)
Yes 9 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
No 82 (23) 27 (29) 13 (33) 2 (7) 5 (14) 9 (20)
No information 258 (74) 65 (71) 26 (67) 25 (93) 30 (86) 35 (80)
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Mortality 43 (13) 7 (8) 3 (8) 8 (30) 9 (26) 5 (11)
Clinical status (WHO
Scales)
38 (11) 0 (0) 0 (0) 0 (0) 2 (6) 3 (7)
Length of
hospitalization
14 (4) 8 (9) 2 (5) 2 (7) 2 (6) 3 (7)
Randomised trials – no. (%)
Yes 275 (79) 49 (53) 19 (49) 13 (48) 16 (46) 26 (59)
No 74 (21) 43 (47) 20 (51) 14 (52) 19 (54) 18 (41)
Multicentre trials – no. (%)
Yes 129 (37) 37 (40) 11 (28) 6 (22) 13 (37) 15 (34)
No 164 (47) 47 (51) 26 (67) 17 (63) 16 (46) 25 (57)
No information 56 (16) 8 (9) 2 (5) 4 (15) 6 (17) 4 (9)
Industry-funded – no. (%)
Yes 73 (21) 12 (13) 9 (23) 2 (7) 6 (17) 7 (16)
No 276 (79) 80 (87) 30 (77) 25 (93) 29 (83) 37 (84)
Median sample size
calculated (IQR) – no.
123.5 (60–333) 120 (72–300) 30 (20–48) 44 (20–190.5) 50 (20–117.5) 70 (40–200)
Median expected trial
duration (IQR) – days
181 (98.5–365) 155 (90–337) 314 (188–437.5) 217 (92–396) 214 (92–364) 262.5 (90–
381.75)
COPD chronic obstructive pulmonary disease, IQR interquartile range
Note: The sum of the columns is higher than 580 because some trials assess more than one intervention
aMost of these trials (93%) specify a minimal inclusion age, without specifying a maximal inclusion age
Fig. 1 Clinical characteristics of participants included in early COVID-19 treatment trials
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trial protocols registered up to April 19th, 2020. Sixty-
six (11.4%) trials were reported as “Completed”, 351
(60.5%) as “Recruiting”, 130 (22.4%) as “Not yet recruit-
ing”, 14 (2.4%) as “Suspended”, 11 (1.9%) as “Termi-
nated”, seven (1.2%) as “Withdrawn”, and for one (0.2%)
the recruitment status was unknown.
Of the 18 trials that stopped prematurely (classified as
“Terminated” or “Withdrawn”) we collected the reasons
for stopping if this was explicit in the registries: six were
due to low accrual, three were due to availability of new
evidence, two for others reason (including, for example,
administrative issues), and seven trials for unknown rea-
sons. Fourteen trials were reported as “Suspended” for
the following reasons: six due to low accrual, one due to
futility, one due to availability of new evidence, three for
other reasons, and three for unknown reasons.
Of the 580 identified treatment trials, 251 (43.3%) had
been planned to be completed before September 14th,
2020; nevertheless only 33 of these (13.1%) reported be-
ing “Completed” on this date. The majority of these
Fig. 2 Methodological characteristics of early COVID-19 treatment trials
Fig. 3 Planned median sample size and trial duration of early COVID-19 treatment trials
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trials remained listed as “Recruiting” (136; 54.2%), 66
(26.3%) as “Not yet recruiting”, six (2.4%) as “Sus-
pended”, seven (2.8%) as “Terminated”, two (0.8%) as
“Withdrawn”, and one (0.4%) was unknown.
Public results were only available for a few trials (46,
7.9%), mainly through journal articles, and only one had
submitted results to the registry. Of these 46 trials, 19
were listed as “Completed” in the registry and two as
“Terminated”, while 22 were still listed as “Recruiting”,
and three as “Not yet recruiting”.
Discussion
On January 30th, 2020, COVID-19 was declared a public
health emergency of international concern and on
March 11th, it was declared a pandemic. As of our initial
search date, April 19th, 1,603,209 cases had been re-
ported worldwide, 54,225 patients were in a serious or
critical state, and 169,750 had died [13]. These numbers
continued to increase hourly as the world raced to miti-
gate the impact of the disease. Our results suggest that a
considerable clinical research effort was mobilized early
on against COVID-19. The hundreds of trials conducted
worldwide offer some hope. To maximise the efficacy of
research in infectious disease epidemics, research must
be fast, flexible, and integrated with the frontline re-
sponse [14].
Adaptive clinical trials may be particularly useful in
the current pandemic [15, 16] as they enable sample
sizes and allocation ratios to be refined, treatments or
doses abandoned, and focus moved towards patients
with a higher likelihood of benefit. A few large trials,
notably, the RECOVERY trial and the WHO Solidarity
trial, are underway and use an adaptive design. Cur-
rently, preliminary results are available confirming the
usefulness of this type of trial design in providing in-
formative evidence, namely showing positive results for
dexamethasone [17] and lack of benefit for hydroxy-
chloroquine [18] and lopinavir/ritonavir [10]. Another
example is the Adaptive COVID-19 Treatment Trial,
(ACTT) [19], sponsored by the National Institute of Al-
lergy and Infectious Diseases (NIAID) that led remdesi-
vir to receive a conditional marketing authorisation by
the European Medicines Agency (EMA) and an initial
Emergency Use Authorization (EUA) followed by formal
approval by the US Food and Drug Administration
(FDA). With these few exceptions, the research we
found seems largely insufficient to provide clear answers
for core outcomes in the shortest possible time. How-
ever, it is important to consider that although limitations
were present from the onset, several protocols were later
revised based on the evolution of the pandemic and in-
creasing knowledge of the disease. The overall impact of
protocol modifications is beyond the objectives of the
present study. Nevertheless, based on the final results of
several studies, most limitations present from the onset
seem to have remained and affect the final publication.
Our results suggest that patients at the largest risk of
death due to COVID-19 were not being prioritised in
clinical trials. This is an important missed opportunity
since the high baseline risk means that smaller treatment
effects would be more easily detected [3]. Therefore, par-
ticipants with a higher likelihood of benefit should not
only be the focus of clinical research from an ethical
point of view but would be the most efficient population
to study in order to identify which treatments are worth-
while pursuing and which are not. Although the focus
on high-risk patients would have been an important
strategy to adopt in early trials, in later trials the inclu-
sion of non-selective patients would be essential to en-
sure the external validity of results.
While most treatment trials use a randomised con-
trolled design, we found that 92 (15.9%) were single-
arm trials. These trials are a matter of concern,
namely as CFR changes considerably over time, and
trials using historical controls will likely lead to more
false-positive findings [20]. Also of concern is the fact
that most treatment trials (58.3%) were not multi-
centric. It is well documented that evidence from
single-centre trials is more prone to bias compared
with multicentre trials, and tend to provide larger
treatment effects [21]. This is particularly clear in the
critical care setting, where many positive single-centre
trials have been contradicted by subsequent multicen-
tre trials [22]. Furthermore, few RCTs conducted in
intensive care units and using mortality as a primary
endpoint show a beneficial impact of the intervention
on the survival of critically ill patients [23].
Another essential aspect of trial design is the choice of
endpoints. While we recognize the importance of surro-
gate endpoints, which allow faster results to be obtained
when compared with core clinical endpoints [24], the
lack of hard and more pragmatic endpoints such as
death and length of hospitalisation are causes for con-
cern. To eschew these more clinically relevant endpoints
is a methodological mistake that is hard to understand.
High-quality information, as straightforward and gener-
alisable as possible, will be key to moving forward. For
research to permit informed clinical decision-making,
this will have to change, and trials must use uniform
disease-related definitions. Of note, several core out-
come sets have been defined since the trial protocols
were first registered [25]. However, these were published
after the first wave of the pandemic in the northern
hemisphere, and therefore beyond the scope of time dur-
ing which these might have been most useful. Neverthe-
less, many treatment trials are a priori already deemed
not to detect statistically significant and clinically rele-
vant results. The median target sample size of assessed
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COVID-19 pharmacotherapy trials is 100 participants.
This is manifestly insufficient to detect anything but an
extremely large treatment effect. For example, regarding
trials with mortality as a primary endpoint, only three
trials were powered to detect a difference of 50% or
more between treatment groups (assuming a baseline
risk of 2%). Even assuming a baseline risk of 10%,
only 38 trials were adequately powered to detect a
difference of 50% or more between treatment groups.
In fact, half of the trials evaluating mortality have a
sample size of 112 participants or fewer and are only
able to identify a treatment effect on mortality over
90% (irrespectively of the baseline risk), which is un-
realistic (supplementary material). Although the re-
sults of underpowered trials can be meta-analysed,
thereby increasing the power to detect a treatment ef-
fect, this approach remains inefficient in terms of
time and overall resources. The results of systematic
reviews and meta-analysis can be threatened by
underpowered trials due to publication bias and re-
lated types of small-study effects [26]. On the other
hand, the planned trial duration is also relatively
short (median of 184 days for overall treatment trials),
given the uncertainty regarding the natural history of
COVID-19.
Some of our concerns have been increased by the early
termination of a clinical trial studying remdesivir, con-
ducted in 10 hospitals in Wuhan, China [27]. This trial
was to enrol 453 participants but as the disease in the
area was brought under control the number of eligible
patients became too small, and recruitment was stopped
at 236 participants. This led to reduced power in the
trial, of only 58%, while it was intended to be 80%. This
trial failed to demonstrate any difference in time to clin-
ical improvement with remdesivir (HR 1.23 [95% CI
0.87–1.75]), while, later on, the ACTT trial, an adaptive,
larger, and adequately powered trial succeeded in show-
ing the usefulness of remdesivir in hospitalized patients
(rate ratio for recovery 1.32 [95% CI 1.12–1.55]) [19].
We found that only 18.9% of treatment trials were
industry-funded. Although trials undertaken on the
initiative of investigators are important, the absence
of experienced industry-supported trials means that
there is considerable room for improvement and
effort by many of these multinational corporations.
Although we are aware of important efforts by the in-
dustry to maintain pharmacotherapies available during
the crisis, these entities have the resources and
experience available to provide an important contribu-
tion in conducting high-quality, high-output clinical
research.
In mid-March 2020, the majority of COVID-19 cases
worldwide were no longer from continental China, and
as of April 19th, 2020, only around 4% of cases were
from China [13]. These figures are in clear contrast with
the fact that so many treatment trials (47.6%) were con-
ducted exclusively in China. Previous research has sug-
gested that a large proportion of clinical trial data
submitted to support new drug registrations in China
may be considered to be incomplete or substandard
[28]. Therefore, despite the large push in research, we
question if the upcoming flood of data is of high enough
quality to produce clear answers to critical questions at
early stages and the necessary recruitment capability.
We are also worried that considerable efforts were
employed in the 92 treatment trials and combined
planned target samples of 18,892 participants studying
the effect of TCM on COVID-19. We would urge that
these resources be used more wisely.
The main pharmacotherapies under investigation were
chloroquine/hydroxychloroquine, antivirals, notably lopi-
navir/ritonavir, and monoclonal antibodies. We found
no substantive methodological differences between trials
evaluating these interventions. However, there are differ-
ences in patients’ clinical characteristics, with monoclo-
nal antibody trials allowing the inclusion of more
patients with several and critical illness, as well as partic-
ipants with relevant comorbidities. Antiviral trials in-
clude relatively fewer patients with several and critical
illness, and largely excluded participants with COVID-
relevant comorbidities.
As of September 14th, 2020, 6 months after the pan-
demic was declared, only a minority of these early trials
made results available to the public. Additionally, ac-
cording to planned completion dates, 251 trials should
have been completed by this date, while only 33 accom-
plished this commitment. This corresponds to much
lower figures than anticipated, considering the trials’
planned follow-up. Moreover, the information on the re-
cruitment status of the trials often seems to not be up-
dated in the registries, rendering it difficult to interpret
the real state of research on this topic. The current avail-
able overall results and status from these early 580 treat-
ment trials reinforce our initial worries about the overall
inadequacy of these trials to provide clinically relevant
conclusions.
Our study has several limitations. First, the data pre-
sented focus exclusively on registered trials. Similarly,
phase 1 trials may be underrepresented. Second, there is
a significant amount of missing or unsubmitted data for
certain data fields, which limits the completeness of the
analyses and thus the interpretability of the results pre-
sented. Third, given the rush to conduct more research,
there may be trials underway that had not yet been reg-
istered, an important issue given the common nature of
retrospective registration [7]. Fourthly, the quality of the
available records was largely poor, with inconsistencies
and errors throughout. We think that most of the issues
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have been resolved, though we cannot be certain that
nothing was missed.
Conclusions
With the hundreds of trials enrolling thousands of
people currently underway, a more efficient and useful
approach would be for research bodies such as the
WHO, NIH, Inserm, etc. to create a coordinated re-
search response to face the pandemic. The EMA has
called for similar efforts [29]. We understand that there
are political, ethical, administrative, contractual, regula-
tory, logistic, economic, and societal factors that may
hinder research, though these difficulties should be over-
come in times of global crisis. Persisting on the path of
isolated investigations will likely only lead to futile trials
and more death on a global scale. Given the large num-
bers of people with COVID-19, and the recent push for
more real-world evidence, we consider that there is an
urgent need for a global high-quality COVID-19 patient
registry, which could be used to detect large beneficial
effects [30] and provide relevant evidence for health care
decision-making [31].
Initiatives such as the WHO R&D Blueprint aim to
tackle the challenge of generating new evidence during
disease outbreaks. We believe that clinical research must
be integrated as an essential element of a coordinated
international response to epidemics. As those are excep-
tionally difficult contexts for clinical research, tools such
as adaptive protocols that could feasibly be integrated
into clinical practice, as well as global research networks
and platforms, may be of great help to produce inform-
ative research. Due to the unpredictable features of new
outbreaks, continued enrolment throughout different
locations should be advocated, this would enable the in-
clusion of sufficient numbers of participants as well as
the combination of research efforts [32].
The current treatment and prophylaxis options are
few and built upon very scarce and fragile data. With the
proper forward planning, critical questions could have
been answered earlier. As clinical investigators, we have
the obligation to adjust and improve the research being
conducted. The world was not ready to react with the
appropriate research to a pandemic. We believe that the
scientific community, the pharmaceutical industry, and
research agencies could have done better.
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